Efficiacy of clinically-used antibody therapies approved by EMA and/or FDY (IMAGE)

Deutsches Primatenzentrum (DPZ)/German Primate Center

Efficiacy of clinically-used antibody therapies approved by EMA and/or FDY

Caption

The Omicron subvariants BA.1, BA.4, BA.5 as well as Q.1.1 have a high number of mutations in the spike protein. Some of these mutations are escape mutations that allow the virus to escape neutralization by antibodies. In addition, resistance to biotechnologically produced antibodies, which are administered to high-risk patients as a preventive measure or as therapy for a diagnosed SARS-CoV-2 infection, is also developing. Omicron sub-lineage BQ.1.1 is the first variant resistant to all antibody therapies currently approved by the EMA (European Medicines Agency) and/or FDA (US Food and Drug Administration).

Credit

Markus Hoffmann, Deutsches Primatenzentrum

Usage Restrictions

The Image is for one-time use in connection with the news release.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.